CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 34 enrolled
Drug / intervention
Ritonavir and Pyramax +1 moredrug
Likely dose
Ritonavir and Pyramax 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01156389
NCT01156389Phase 1Completed
CompareCT.gov

Open-label, Randomised, Drug Interaction Study of Pyramax (Pyronaridine Artesunate) and the Protease Inhibitor Ritonavir in Healthy Volunteers

Medicines for Malaria Venture·interventional·Posted Jul 2, 2010·Updated Feb 3, 2023

In Brief

A Phase 1 clinical trial evaluating Ritonavir and Pyramax and Pyramax for Malaria. Completed, enrolled 34 participants across 1 site.

Detailed Summary

The primary objective of the study is to determine any drug interaction between the antimalarial Pyramax (pyronaridine artesunate) and the protease inhibitor ritonavir in healthy subjects. The secondary objective of the study is to assess further the safety of Pyramax in this setting.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMalaria
CountriesSwitzerland
CollaboratorsShin Poong Pharmaceuticals

Timeline

Phase 1CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedJul 2, 2010
Enrollment StartJul 1, 2010
Primary CompletionAug 1, 2010
Study CompletionSep 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 16 years ago

Interventions

Ritonavir and Pyramaxdrug

100 mg ritonavir (one soft gelatin capsule twice per day over 17 days, the evening capsule on day 1 will be omitted) and Pyramax (pyronaridine/artesunate) 180:60 mg (3 to 4 tablets once per day according to weight for 3 days).

Pyramaxdrug

Pyramax (pyronaridine/artesunate) 180:60 mg (3 to 4 tablets once per day according to weight for 3 days).